iRadimed (NASDAQ:IRMD) CEO Sells $226,500.00 in Stock

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 2,500 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $90.60, for a total value of $226,500.00. Following the completion of the transaction, the chief executive officer directly owned 2,162,500 shares of the company’s stock, valued at approximately $195,922,500. This trade represents a 0.12% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

iRadimed Stock Down 1.6%

Shares of IRMD stock traded down $1.45 on Tuesday, hitting $90.61. The company had a trading volume of 126,583 shares, compared to its average volume of 120,042. The firm has a market cap of $1.16 billion, a P/E ratio of 51.07 and a beta of 0.90. The company has a 50-day moving average price of $91.71 and a 200-day moving average price of $95.47. iRadimed Corporation has a twelve month low of $55.11 and a twelve month high of $107.90.

iRadimed (NASDAQ:IRMD) last announced its quarterly earnings results on Friday, May 1st. The medical equipment provider reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.46 by $0.03. The company had revenue of $21.98 million during the quarter, compared to analysts’ expectations of $21.32 million. iRadimed had a return on equity of 24.48% and a net margin of 27.36%.iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. Equities research analysts expect that iRadimed Corporation will post 1.52 EPS for the current year.

iRadimed Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, May 29th. Investors of record on Friday, May 15th were given a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 0.9%. The ex-dividend date was Friday, May 15th. iRadimed’s dividend payout ratio (DPR) is currently 43.72%.

Hedge Funds Weigh In On iRadimed

Several institutional investors and hedge funds have recently modified their holdings of IRMD. Quarry LP purchased a new position in shares of iRadimed in the 3rd quarter valued at about $40,000. Farther Finance Advisors LLC increased its stake in shares of iRadimed by 827.1% in the 4th quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider’s stock valued at $43,000 after purchasing an additional 397 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in shares of iRadimed by 191.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock valued at $45,000 after purchasing an additional 495 shares in the last quarter. CWM LLC increased its stake in shares of iRadimed by 19.5% in the 4th quarter. CWM LLC now owns 657 shares of the medical equipment provider’s stock valued at $64,000 after purchasing an additional 107 shares in the last quarter. Finally, State of Wyoming purchased a new position in shares of iRadimed in the 3rd quarter valued at about $72,000. Hedge funds and other institutional investors own 92.34% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on the company. Lake Street Capital reiterated a “buy” rating and set a $120.00 price target on shares of iRadimed in a research report on Wednesday, February 11th. Freedom Capital upgraded iRadimed to a “strong-buy” rating in a research report on Thursday, April 2nd. Weiss Ratings lowered iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a research note on Wednesday, May 20th. Finally, Roth Mkm restated a “buy” rating and issued a $120.00 price target on shares of iRadimed in a research note on Tuesday, February 10th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, iRadimed currently has a consensus rating of “Buy” and an average target price of $120.00.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.